Disclosures for "Long-term Survival in a WHO Grade 4 IDH-mutant Astrocytoma Using a Farnesyltransferase Inhibitor in Combination with Temozolomide"
-
Dr. Garcia has nothing to disclose.
-
Ms. Knight has nothing to disclose.
-
Dr. Puduvalli has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Insightec . Dr. Puduvalli has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novocure. Dr. Puduvalli has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bayer. An immediate family member of Dr. Puduvalli has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Newave . Dr. Puduvalli has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Servier. Dr. Puduvalli has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Insightec, Novocure, Bayer, Servier, . An immediate family member of Dr. Puduvalli has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Newave . Dr. Puduvalli has stock in Gilead. Dr. Puduvalli has stock in Moderna. The institution of Dr. Puduvalli has received research support from Merck, Servier, Bexion, Karyopharm, Samus therapeutics.
-
Dr. Kamiya-Matsuoka has nothing to disclose.